Douglas S. Chapin

2.7k citations

36 papers · 2.1k indexed · h-index 21

Molecular Biology top 5%
Pharmacology top 1%
Organic Chemistry top 5%
Cellular and Molecular Neuroscience top 5%
Psychiatry and Mental health top 10%

Co-authors: Sheryl A. McCarthy Judith A. Siuciak Frank S. Menniti Christopher J. Schmidt John F. Harms A. Martin Lorraine A. Lebel Kenneth E. Moore
Topics: Cholinesterase and Neurodegenerative Diseases (15 papers)Phosphodiesterase function and regulation (13 papers)Receptor Mechanisms and Signaling (8 papers)
Cited by: Biological Psychiatry Pharmacology Behavioral Neuroscience
Journals: Journal of the American Chemical Society Journal of Neuroscience The Journal of Physical Chemistry
Partner nations: United States Denmark Germany

In The Last Decade

Douglas S. Chapin

36 papers receiving 2.1k citations

Peers

Countries citing papers authored by Douglas S. Chapin

Since Specialization

Citations

This map shows the geographic impact of Douglas S. Chapin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas S. Chapin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas S. Chapin more than expected).

Fields of papers citing papers by Douglas S. Chapin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas S. Chapin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas S. Chapin. The network helps show where Douglas S. Chapin may publish in the future.

Co-authorship network of co-authors of Douglas S. Chapin

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas S. Chapin. A scholar is included among the top collaborators of Douglas S. Chapin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas S. Chapin. Douglas S. Chapin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reduction of Brain Kynurenic Acid Improves Cognitive Function 2014 ·Journal of Neuroscience ·Rouba Kozak,Brian Campbell,Christine A. Strick,W. Elliott Horner,William E. Hoffmann,Tamás Kiss,Douglas S. Chapin,(unknown),Amanda Abbott,Bradley M. Roberts,Kari R. Fonseca,Victor Guanowsky,Deborah Young,P A Seymour,Amy B. Dounay,Mihály Hajós,Graham V. Williams,Stacy A. Castner	137
2	Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 H -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1). 2009 ·Journal of Medicinal Chemistry ·Patrick R. Verhoest,Douglas S. Chapin,Michael L. Corman,Kari R. Fonseca,John F. Harms,Xinjun Hou,Eric S. Marr,Frank S. Menniti,Frederick Nelson,Rebecca E. O’Connor,Jayvardhan Pandit,(unknown),Anne W. Schmidt,Christopher J. Schmidt,(unknown),Spiros Liras	172
3	Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia 2008 ·Journal of Pharmacology and Experimental Therapeutics ·C J Schmidt,Douglas S. Chapin,(unknown),Michael L. Corman,Mihály Hajós,John F. Harms,William E. Hoffman,Lorraine A. Lebel,Sheryl A. McCarthy,(unknown),(unknown),Mark J. Majchrzak,Andres D. Ramirez,Karl T. Schmidt,P A Seymour,Judith A. Siuciak,F. David Tingley,Robert D. Williams,Patrick R. Verhoest,Frank S. Menniti	238
4	Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme 2007 ·Psychopharmacology ·Judith A. Siuciak,Sheryl A. McCarthy,Douglas S. Chapin,A. Martin	92
5	Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme 2007 ·Psychopharmacology ·Judith A. Siuciak,Douglas S. Chapin,Sheryl A. McCarthy,A. Martin	73
6	Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background 2007 ·Neuropharmacology ·Judith A. Siuciak,Sheryl A. McCarthy,Douglas S. Chapin,A. Martin,John F. Harms,Christopher J. Schmidt	49
7	Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme 2007 ·Neuropharmacology ·Judith A. Siuciak,Sheryl A. McCarthy,Douglas S. Chapin,Tracy M. Reed,Charles V. Vorhees,David R. Repaske	48
8	Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits 2007 ·Psychopharmacology ·Judith A. Siuciak,Sheryl A. McCarthy,A. Martin,Douglas S. Chapin,Jeffrey L. Stock,(unknown),(unknown),(unknown),Stafford McLean	43
9	Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis 2006 ·Neuropharmacology ·Judith A. Siuciak,Douglas S. Chapin,John F. Harms,Lorraine A. Lebel,Sheryl A. McCarthy,Leslie K. Chambers,Alka Shrikhande,Stephen K.-F. Wong,Frank S. Menniti,Christopher J. Schmidt	226
10	Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function 2006 ·Neuropharmacology ·Judith A. Siuciak,Sheryl A. McCarthy,Douglas S. Chapin,(unknown),Larry C. James,Robert D. Williams,Jeffrey L. Stock,John D. McNeish,Christine A. Strick,Frank S. Menniti,Christopher J. Schmidt	196
11	Evaluation of Ability of Biochemical Markers of Bone Turnover to Predict a Response to Increased Doses of HRT 2004 ·Calcified Tissue International ·Harold N. Rosen,Robert A. Parker,S. L. Greenspan,Ikechukwu Iloputaife,(unknown),Douglas S. Chapin,(unknown),Bruce Kessel,Per Qvist,Michael Rosenblatt	6
12	Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease 2003 ·European Journal of Pharmacology ·Dane Liston,Jann A. Nielsen,Anabella Villalobos,Douglas S. Chapin,Shawn B. Jones,(unknown),Ismail A. Shalaby,Andres D. Ramirez,Deane M. Nason,William F. White	173
13	Teaching sacrospinous colpopexy 1997 ·American Journal of Obstetrics and Gynecology ·Douglas S. Chapin	11
14	5,7-Dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[3,2-f]-1,2-benzisoxazol-6-one: A Potent and Centrally-Selective Inhibitor of Acetylcholinesterase 1995 ·Journal of Medicinal Chemistry ·(unknown),Todd W. Butler,Douglas S. Chapin,(unknown),(unknown),Jeffrey L. Ives,Susan B. Jones,Dane Liston,A. Nagel	36
15	Novel Benzisoxazole Derivatives as Potent and Selective Inhibitors of Acetylcholinesterase 1994 ·Journal of Medicinal Chemistry ·Anabella Villalobos,James F. Blake,Christopher K. Bíggers,Todd W. Butler,Douglas S. Chapin,Yuhpyng L. Chen,Jeffrey L. Ives,Shawn B. Jones,Dane Liston	92
16	Syntheses and Anticholinesterase Activity of Tetrahydrobenzazepine Carbamates 1994 ·Journal of Medicinal Chemistry ·(unknown),Dane Liston,Jonas B. Nielsen,Douglas S. Chapin,A. DUNAISKIS,Kenneth Hedberg,(unknown),Jillian G. Johnson,Sarah Jones	12
17	Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl-2-imidazolidinones 1991 ·Journal of Medicinal Chemistry ·Nicholas A. Saccomano,Fredric J. Vinick,B. Kenneth Koe,J.A. Nielsen,(unknown),Martin L. Meltz,D. Z. Phillips,(unknown),(unknown),Douglas S. Chapin,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	39
18	Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase 1991 ·Journal of Medicinal Chemistry ·John Lowe,Robert Archer,Douglas S. Chapin,(unknown),(unknown),Jeff Johnson,B. Kenneth Koe,Lorraine A. Lebel,Peter F. Moore	77
19	Exogenous Tryptophan Increases Synthesis, Storage, and Intraneuronal Metabolism of 5‐Hydroxytryptamine in the Rat Hypothalamus 1986 ·Journal of Neurochemistry ·K.J. Lookingland,Nancy Shannon,Douglas S. Chapin,Kenneth E. Moore	59
20	The Surface Catalysis of the Ortho- to Para- Conversion in Hydrogen under Pressure at Low Temperatures 1957 ·Journal of the American Chemical Society ·Douglas S. Chapin,Herrick L. Johnston	14

About Douglas S. Chapin

Douglas S. Chapin is a scholar working on Biological Psychiatry, Pharmacology and Organic Chemistry, having authored 36 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cholinesterase and Neurodegenerative Diseases (15 papers), Phosphodiesterase function and regulation (13 papers) and Receptor Mechanisms and Signaling (8 papers). The work is most often cited by research in Biological Psychiatry (154 citations), Pharmacology (883 citations) and Behavioral Neuroscience (101 citations). Douglas S. Chapin has collaborated with scholars based in United States, Denmark and Germany. Frequent co-authors include Sheryl A. McCarthy, Judith A. Siuciak, Frank S. Menniti, Christopher J. Schmidt, John F. Harms, A. Martin, Lorraine A. Lebel, Kenneth E. Moore, Dane Liston and Robert D. Williams. Their work appears in journals such as Journal of the American Chemical Society, Journal of Neuroscience and The Journal of Physical Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact